Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. Based on the Canopy Growth Corporation stock forecasts from 14 analysts, the average analyst target price for Canopy Growth Corporation is CAD 9.77 over the next 12 months. Canopy Growth Corporation’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Canopy Growth Corporation is Neutral, which is based on 2 positive signals and 2 negative signals. At the last closing, Canopy Growth Corporation’s stock price was CAD 6.05. Canopy Growth Corporation’s stock price has changed by -14.67% over the past week, -18.35% over the past month and -80.76% over the last year.

1. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
WEED:CA:TSX (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | TSX | Common Stock
Values as of 30th May, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Last Close
CAD 6.05
Change
-0.10(-1.63%)
Market Cap
CAD 2.45B
1 Yr Capital Gain
-80.00%
1 Yr Dividend Return
N/A
1 Yr Total Return
-80.00%
Earning Growth (5 yr)
N/A
Average Target Price
9.77(+61.50% )
Average Analyst
Rating
Under-perform
Fundamental
Analysis
Neutral
Our view of the stock is Neutral with a score of 5 out of 10, where 0 is very bearish and 10 very bullish
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What to not like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.

2. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
WEED:CA:TSX (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
WEED:CA
Canopy Growth Corporation
-80.8% 0 -80.8%
XIU:CA
iShares S&P/TSX 60 Index ETF
+6.4% +2.8% +9.2%
Company Overview
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based
products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments,
Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel
capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel,
DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a
strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical
research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the
mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to
Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

3. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.canopygrowth.com
Address
1 Hershey Drive, Smiths Falls, ON, Canada, K7A 0A8
Fiscal Year End
March
Technical Indicators
Value Value
Beta 1.98 52 Week High 32.60
Short Ratio 6.61 52 Week Low 5.85
Shorted Shares 13,634,480 200 Day Moving Average 12.84
Shorted Shares Previous Month 13,156,435 50 Day Moving Average 8.05
Shares Held By Insiders 3,578.50% Short Percentage 3.00%
Shares Held by Institutions 17.62 Dividend Yield N/A

4. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
WEED:CA:TSX (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Market Performance
Market Performance vs. Industry / Classification (Drug Manufacturers-Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -45.20% -32.9% 39% -8.0% 3%
Dividend Return N/A 0.7% N/A 1.1% N/A
Total Return -45.20% -32.9% 39% -7.4% 3%
Trailing 12 Months
Capital Gain -80.00% -63.6% 31% -5.1% 1%
Dividend Return N/A 0.8% N/A 2.6% N/A
Total Return -80.00% -63.6% 31% -3.4% 1%
Trailing 5 Years
Capital Gain -18.79% -45.7% 82% 9.1% 23%
Dividend Return N/A N/A N/A 11.3% N/A
Total Return -18.79% -45.7% 82% 21.1% 19%
Average Annual (5 Year Horizon)
Capital Gain 44.31% -5.9% 97% 4.6% 94%
Dividend Return N/A 0.2% N/A 1.8% N/A
Total Return 44.31% -5.9% 97% 6.2% 94%
Risk Return Profile
Volatility (Standard
Deviation)
146.37% 39.0% 10% 16.0% 4%
Risk Adjusted Return 30.27% N/A 90% 40.5% 39%
Market Capitalization 2.45B 0.08B 94% 0.46B 77%

5. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio N/A 41.5 N/A 13.5 N/A
pbratio 0.7 0.8 61% 1.5 86%
pcfratio -4.5 -1.6 74% 7.5 83%
pfcfratio N/A 12.4 N/A 9.6 N/A
Management Effectiveness
retequity -8.43% -41.9% 71% 9.0% 20%
retinvcap 0.35% -20.5% 83% 4.2% 40%
retass -6.06% -7.0% 61% 2.5% 15%
debtequityratio N/A 9.7% N/A 50.8% N/A
Technical Ratios
yield N/A 5.4% N/A 3.5% N/A
sratio 6.61 5.40 45% 1.73 18%
spercent 5.42% 0.7% 4% 2.1% 41%
beta 1.98 1.51 21% 1.03 11%

6. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
WEED:CA:TSX (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Reiterates STA Research Hold CAD 8.75 2022-05-30
Target Morningstar Buy CAD 20 2022-05-30
Target Down CIBC Capital Markets Underperform CAD 5 2022-05-30
Target Down Stifel Nicolaus Research Sell CAD 5 2022-05-30
Target Down Cowen Buy CAD 6.5 2022-05-30
Reiterated by Cfra Hold CAD 10 2022-05-28
Downgrades Canaccord Capital Sell CAD 6 2022-05-24
Downgrades Alliance Global Partners Hold CAD 8 2022-05-20
Target Down Eight Capital Sell CAD 5.5 2022-05-20
Adjusts STA Research Hold CAD 8.75 2022-05-19
Target Down CIBC Capital Markets Underperform CAD 6.5 2022-05-19
Target Down Stifel Nicolaus Research Sell CAD 7.5 » CAD 6 2022-05-02
Target Down Bank of America Underperform CAD 8.5 2022-04-07
Maintains STA Research Buy CAD 15 2022-03-23
Target BMO Financial Hold CAD 11 2022-02-18
Target Down Stifel Nicolaus Research Sell CAD 7.5 2022-02-11
Target Down Cowen Buy CAD 12.5 2022-02-11
Target Down Canaccord Capital Hold CAD 30 » CAD 10 2022-02-10
Target STA Research Speculative Buy CAD 15 2022-02-08
Target Down MKM Partners Buy CAD 17 2022-02-08
Target Down CIBC Capital Markets Underperform CAD 9 2022-02-03
Target Down Alliance Global Partners Buy CAD 11 2022-01-07
Downgraded Bank of America Underperform CAD 24 » CAD 13 2021-12-22
Downgraded Piper Sandler Underweight CAD 14 » CAD 9 2021-12-20
Assigned Wells Fargo Underweight 2021-12-07

7. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
WEED:CA:TSX (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Annual Financial (CAD)

8. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
WEED:CA:TSX (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Quarterly Financial (CAD)

9. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
WEED:CA:TSX (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Largest Industry Peers for Drug Manufacturers-Specialty & Generic
Symbol Company Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc +0.42 (+3.3%) CAD 4.69B
APHA:CA Aphria Inc N/A CAD 4.44B
TLRY:CA Tilray Inc +0.08 (+1.4%) CAD 2.89B
CRON:CA Cronos Group Inc -0.14 (-3.6%) CAD 1.45B
GUD:CA Knight Therapeutics Inc +0.05 (+0.9%) CAD 0.62B
ACB:CA Aurora Cannabis Inc +0.06 (+2.8%) CAD 0.49B
HLS:CA HLS Therapeutics Inc +1.40 (+9.9%) CAD 0.46B
OGI:CA OrganiGram Holdings Inc +0.03 (+2.1%) CAD 0.46B
INCR-U:CA InterCure Ltd N/A CAD 0.31B
TH:CA Theratechnologies Inc +0.09 (+2.9%) CAD 0.30B
ETFs Containing WEED:CA
Symbol Company Name Weight Mer Price(Change) Market Cap
PZC:CA Invesco FTSE RAFI Canadian Sma.. 0.00 % 0.67 % N/A CAD 8.00M
HMMJ:CA Horizons Marijuana Life Scienc.. 0.00 % 0.86 % -0.03 (0.0%) CAD 0.18B
SEED:CA Evolve Marijuana Fund 0.00 % 1.13 % N/A CAD 3.63M
HMMJ-U:CA Horizons Marijuana Life Scienc.. 0.00 % 0.00 % N/A N/A
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%